Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on RegenXBio (RGNX – Research Report) and Autolus Therapeutics (AUTL – Research Report). RegenXBio (RGNX) Wedbush analyst Andreas Argyrides maintained a Hold rating on RegenXBio today and set a price target of $32.00. The company's shares closed last Thursday at $34.74. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-regenxbio-rgnx-and-autolus-therapeutics-autl?utm_source=advfn.com&utm_medium=referral
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more REGENXBIO Charts.
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more REGENXBIO Charts.